EUVIMEDEUVIMED entdecken
Metaanalyse

Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta‐analysis of randomized controlled trials

Ying-Ying Zhang iD, Min Zhang iD, Jia-Qi Zhang, Qiu-Qi Li, Mei-Ping Lu iD, Lei Cheng iD

International Forum of Allergy & Rhinology · 2024-04 · 14 (4) · 794-806

DOI: 10.1002/alr.23268 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 16.09.2023. Verfasst von Ying-Ying Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Omalizumab, Randomized Controlled Trials as Topic, Desensitization, Immunologic, Anti-Allergic Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Jiangsu Province Capability Improvement Project through Science, Technology and Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergen immunotherapy (AIT)‐associated adverse events (AEs) limit its usage in the management of allergic diseases. The monoclonal anti‐IgE antibody (omalizumab) and AIT have complementary actions. However, no consensus has been reached on whether their combination could exert superior efficacy and safety.

Objective

To evaluate whether the combination of AIT with omalizumab is superior to AIT alone in treating allergic diseases.

Methods

The MEDLINE/PubMed, Embase, Scopus and Cochrane Library databases were searched to identify randomized control trials (RCTs) reporting the outcomes of omalizumab combined with AIT (omalizumab + AIT) versus AIT alone. A random‐effect model was established to estimate outcomes with a 95% confidence interval (CI).

Results

A total of 11 eligible RCTs (involving 901 patients) were screened out for the meta‐analysis. According to a pooled analysis, omalizumab + AIT significantly increased the number of patients achieving the target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergens (odds ratio [OR] = 2.43; 95% CI: 1.33–4.44; p = 0.004; I 2 = 35%, and OR = 6.77; 95% CI: 2.10–21.80; p = 0.001; I 2 = 36%, respectively). Similarly, individuals receiving the combination therapy reported significantly fewer episodes of severe systemic AEs than AIT alone (OR = 0.32; 95% CI: 0.18–0.59; p = 0.0003; I 2 = 0%). Meanwhile, the improvements in symptom severity score (mean difference [MD] = −0.26), rescue medication daily means score (MD = −0.14), and number of patients consuming epinephrine in AIT (OR = 0.20) were all more evident than those in AIT alone.

Conclusion

Omalizumab + AIT can significantly enhance the efficacy and safety of AIT by increasing TMD and SU to allergens, while decreasing severe systemic AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabRandomized Controlled Trials as TopicDesensitization, ImmunologicAnti-Allergic AgentsHumansHypersensitivityTreatment OutcomeCombined Modality Therapy

Stichwörter der Autor:innen

Allergen immunotherapyallergic rhinitisanti‐IgEasthmafood allergyomalizumab

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
  • International Centre for Allergy Research, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Ying-Ying Zhang, Min Zhang, Mei-Ping Lu, Lei Cheng

Förderung

  • Jiangsu Province Capability Improvement Project through Science, Technology and Education

Zitieren

APA

Zhang, Y. Y., Zhang, M., Zhang, J. Q., Li, Q. Q., Lu, M. P., & Cheng, L. (2024). Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta‐analysis of randomized controlled trials. International Forum of Allergy & Rhinology, 14(4), 794-806. https://doi.org/10.1002/alr.23268

Vancouver

Zhang YY, Zhang M, Zhang JQ, Li QQ, Lu MP, Cheng L. Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta‐analysis of randomized controlled trials. International Forum of Allergy & Rhinology. 2024;14(4):794-806. doi:10.1002/alr.23268

BibTeX
@article{Zhang2024,
  author = {Zhang, Ying-Ying and Zhang, Min and Zhang, Jia-Qi and Li, Qiu-Qi and Lu, Mei-Ping and Cheng, Lei},
  title = {Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta‐analysis of randomized controlled trials},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  volume = {14},
  number = {4},
  pages = {794--806},
  doi = {10.1002/alr.23268}
}
Kostenlos starten →